Alkermes plc (ALKS) Receives Price Target

Alkermes plc (ALKS) stock is expected to deviate a maximum of $3.06 from the average target price of $62.67 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $66 and the most muted being $60.

Alkermes plc (ALKS) : 4 analysts are covering Alkermes plc (ALKS) and their average rating on the stock is 1.83, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock.


Also, Barclays maintains its view on Alkermes plc (NASDAQ:ALKS) according to the research report released by the firm to its investors. The shares have now been rated Overweight by the stock experts at the ratings house. Barclays raises the price target from $65 per share to $66 per share on Alkermes plc. The rating by the firm was issued on July 29, 2016.

Alkermes plc (NASDAQ:ALKS): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $43.98 and $43.69 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $44.80. The buying momentum continued till the end and the stock did not give up its gains. It closed at $44.74, notching a gain of 2.22% for the day. The total traded volume was 691,580 . The stock had closed at $43.77 on the previous day.

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.